#

Small caps

: 1220
The company also reported a bottom-line loss and missed top-line expectations for the second quarter / Photo: Facebook/SHOTSPOTTER
Small Caps·
AI security solutions provider SoundThinking sinks 25% on lowered 2026 guidance
Playboy has evolved into essentially a brand and licensing company with a growing lingerie retail arm / Photo: Yuphayao Poohs / Shutterstock.com
Small Caps·
Small caps last week: Playboy's pivot, AbCellera trial win, GLP-1 boon for AirSculpt
Morgan Stanley has initiated coverage on ACHV with an overweight rating, citing the company’s smoking cessation agent, cytisinicline / Photo: Unsplash / JJ Shev
Small Caps·
Morgan Stanley sees 80% upside for anti-smoking drugmaker Achieve Life Sciences
The fund is betting on AI infrastructure / Photo: Igor Omilaev / Unsplash
Small Caps·
How Needham's Small Cap Growth Fund is benefitting from the AI boom
Two Wall Street firms have turned cautious on Gap stock / Photo: Facebook / GAP
Small Caps·
Jefferies and Barclays downgrade Gap to 'hold' as 'Barbie magic' not panning out
All four of Marexs reporting segments posted double-digit (and even triple-digit) revenue growth in 2Q26 / Photo: Screenshot from a Nasdaq video
Small Caps·
Financial services firm Marex rockets to all-time high thanks to volatility in 2Q
Backblaze positions itself as an infrastructure provider for the AI market / Photo: Nasdaq Exchange / X
Small Caps·
How small-cap Backblaze is taking on the tech giants in the cloud storage market
Rapid weight loss can leave some patients with loose skin that requires removal or tightening / Photo: Unsplash/karelys Ruiz
Small Caps·
AirSculpt jumps 17% thanks to mooted higher plastic surgery demand amid GLP-1 boom
Playboy has evolved into essentially a brand and licensing company with a growing lingerie retail arm / Photo: AxlGTj / Shutterstock.com
Small Caps·
Playboy rallies 15% as 2Q results indicate licensing model starting to pay off
The companys experimental shot reduced the frequency and severity of hot flashes over a four-week study compared with a placebo, with no serious side effects / Photo: AbCellera
Small Caps·
Mid-cap hot-flash drugmaker AbCellera soars on upbeat mid-stage clinical data
Sionna will now shelve its cystic fibrosis drug candidate / Photo: LinkedIn/Sionna Therapeutics
Small Caps·
Sionna's cystic fibrosis drug candidate fails in trial; stock craters 90%
The first ETF with a portfolio built with an AI model debuted in October 2017 / Photo: Shutterstock.com
Small Caps·
AI-managed investing: Which smid-cap funds have outperformed the Russell 2000 YTD?
Load more